{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:26:34Z","timestamp":1791563194127,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100020771","name":"Natural Science Foundation for Young Scientists of Shanxi Province","doi-asserted-by":"publisher","award":["20210302124693"],"award-info":[{"award-number":["20210302124693"]}],"id":[{"id":"10.13039\/501100020771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072262"],"award-info":[{"award-number":["82072262"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>\n                        <jats:italic>Abstract<\/jats:italic>\n                     <\/jats:title><jats:p>The imbalance between regulatory T (Treg) cells and efficient T cells plays an important role in psoriasis. Low-dose interleukin (IL)-2 can preferentially activate Treg cells and ameliorate the imbalance of Treg\/efficient T cells. This study focused on the status of circulating CD4<jats:sup>+<\/jats:sup>\u2009T subsets and the clinical efficacy of low-dose IL-2 therapies in psoriasis. This retrospective study included peripheral blood samples obtained from 45 psoriatic patients and 40 healthy controls. The 45 psoriatic patients received three cycles of subcutaneous low-dose IL-2 treatment (0.5 million IU\/day for 2\u00a0weeks) combined with conventional therapies. Inflammatory indices, CD4<jats:sup>+<\/jats:sup> T-lymphocyte subsets, and cytokines were measured in all patients before and after treatment. The percentage of Treg cells was dramatically decreased in the psoriasis group compared to the healthy group, and the percentage of Treg cells negatively correlated with the disease indices and the Psoriasis Area and Severity Index (PASI) (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). The Th17\/Treg ratio was significantly increased in the psoriasis group compared to the healthy group, and the Th17\/Treg ratio positively correlated with disease indices and PASI (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Low-dose IL-2 treatment significantly amplified the percentage of Treg cells and restored the Th17 and Treg immune balance in psoriasis (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Low-dose IL-2 combination therapy effectively improved the clinical manifestations of psoriasis but decreased the inflammatory indicators of the disease activity, with no apparent side effects. Thus, low-dose IL-2 provides a new strategy for the treatment of psoriasis.<\/jats:p>","DOI":"10.1007\/s10753-023-01883-6","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T16:56:27Z","timestamp":1692377787000},"page":"2359-2373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Low-dose Interleukin-2 For Psoriasis Therapy Based on the Regulation of Th17\/Treg Cell Balance in Peripheral Blood"],"prefix":"10.1007","volume":"46","author":[{"given":"Zusha","family":"Qiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenpeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"issue":"1","key":"1883_CR1","doi-asserted-by":"publisher","first-page":"7526","DOI":"10.1038\/s41598-019-43899-9","volume":"9","author":"SC Furiati","year":"2019","unstructured":"Furiati, S.C., J.S. Catarino, M.V. Silva, R.F. Silva, R.B. Estevam, R.B. Teodoro, S.L. Pereira, M. Ataide, V. Rodrigues Jr., and D.B.R. Rodrigues. 2019. Th1, Th17, and Treg responses are differently modulated by TNF-\u03b1 inhibitors and methotrexate in psoriasis patients. Scientific Reports 9 (1): 7526.","journal-title":"Scientific Reports"},{"issue":"1","key":"1883_CR2","first-page":"24","volume":"10","author":"R Soleimani","year":"2020","unstructured":"Soleimani, R., M. Mohammadi, S.A. Saghebi, A. Taghipour, A. Khorsand Vakilzadeh, and J. Tavakkol Afshari. 2020. Comparison of Th1\/Th2 and Treg\/Th17 ratios between wet and dry cupping therapies in Persian medicine. Avicenna Journal of Phytomedicine 10 (1): 24\u201334.","journal-title":"Avicenna Journal of Phytomedicine"},{"issue":"7","key":"1883_CR3","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.3390\/ijms21072582","volume":"21","author":"M Komine","year":"2020","unstructured":"Komine, M. 2020. Recent advances in psoriasis research; the clue to mysterious relation to gut microbiome. International Journal of Molecular Sciences 21 (7): 2582.","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"1883_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1684\/ejd.2021.4050","volume":"31","author":"X Zhao","year":"2021","unstructured":"Zhao, X., J. Jiao, X. Li, R. Hou, J. Li, X. Niu, R. Liu, X. Yang, J. Li, J. Liang, et al. 2021. Immunomodulatory effect of psoriasis-derived dermal mesenchymal stem cells on TH1\/TH17 cells. European Journal of Dermatology: EJD 31 (3): 318\u2013325.","journal-title":"European Journal of Dermatology: EJD"},{"key":"1883_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cytogfr.2022.06.003","volume":"67","author":"P Zhou","year":"2022","unstructured":"Zhou, P. 2022. Emerging mechanisms and applications of low-dose IL-2 therapy in autoimmunity. Cytokine and Growth Factor Reviews 67: 80\u201388.","journal-title":"Cytokine and Growth Factor Reviews"},{"issue":"21","key":"1883_CR6","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.3390\/ijms21218011","volume":"21","author":"X Zhu","year":"2020","unstructured":"Zhu, X., and J. Zhu. 2020. CD4 T helper cell subsets and related human immunological disorders. International Journal of Molecular Sciences 21 (21): 8011.","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"1883_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/imr.12935","volume":"300","author":"CA Spinner","year":"2021","unstructured":"Spinner, C.A., and V. Lazarevic. 2021. Transcriptional regulation of adaptive and innate lymphoid lineage specification. Immunological Reviews 300 (1): 65\u201381.","journal-title":"Immunological Reviews"},{"key":"1883_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fimmu.2018.00045","volume":"9","author":"K Xu","year":"2018","unstructured":"Xu, K., W.Y. Yang, G.K. Nanayakkara, Y. Shao, F. Yang, W. Hu, E.T. Choi, H. Wang, and X. Yang. 2018. GATA3, HDAC6, and BCL6 regulate FOXP3+ Treg plasticity and determine Treg conversion into either novel antigen-presenting cell-like Treg or Th1-Treg. Frontiers in Immunology 9: 45.","journal-title":"Frontiers in Immunology"},{"key":"1883_CR9","doi-asserted-by":"publisher","first-page":"3069521","DOI":"10.1155\/2018\/3069521","volume":"2018","author":"L Ma","year":"2018","unstructured":"Ma, L., H. Xue, T. Gao, M. Gao, and Y. Zhang. 2018. Notch1 signaling regulates the Th17\/Treg immune imbalance in patients with psoriasis vulgaris. Mediators of Inflammation 2018: 3069521.","journal-title":"Mediators of Inflammation"},{"issue":"3","key":"1883_CR10","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/sji.12404","volume":"83","author":"L Zhang","year":"2016","unstructured":"Zhang, L., Y. Li, X. Yang, J. Wei, S. Zhou, Z. Zhao, J. Cheng, H. Duan, T. Jia, Q. Lei, et al. 2016. Characterization of Th17 and FoxP3(+) Treg cells in paediatric psoriasis patients. Scandinavian Journal of Immunology 83 (3): 174\u2013180.","journal-title":"Scandinavian Journal of Immunology"},{"issue":"1","key":"1883_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.clim.2009.11.008","volume":"135","author":"L Zhang","year":"2010","unstructured":"Zhang, L., X.Q. Yang, J. Cheng, R.S. Hui, and T.W. Gao. 2010. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clinical Immunology 135 (1): 108\u2013117.","journal-title":"Clinical Immunology"},{"issue":"1","key":"1883_CR12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bjd.19380","volume":"184","author":"L Nussbaum","year":"2021","unstructured":"Nussbaum, L., Y.L. Chen, and G.S. Ogg. 2021. Role of regulatory T cells in psoriasis pathogenesis and treatment. The British Journal of Dermatology 184 (1): 14\u201324.","journal-title":"The British Journal of Dermatology"},{"issue":"17","key":"1883_CR13","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.3390\/jcm10173880","volume":"10","author":"N Kanda","year":"2021","unstructured":"Kanda, N., T. Hoashi, and H. Saeki. 2021. The defect in regulatory T cells in psoriasis and therapeutic approaches. Journal of Clinical Medicine 10 (17): 3880.","journal-title":"Journal of Clinical Medicine"},{"issue":"1","key":"1883_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jid.2020.04.031","volume":"141","author":"A Schwarz","year":"2021","unstructured":"Schwarz, A., R. Philippsen, and T. Schwarz. 2021. Induction of regulatory T cells and correction of cytokine disbalance by short-chain fatty acids: Implications for psoriasis therapy. The Journal of Investigative Dermatology 141 (1): 95-104.e2.","journal-title":"The Journal of Investigative Dermatology"},{"issue":"5","key":"1883_CR15","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.4049\/jimmunol.0803721","volume":"183","author":"WA Goodman","year":"2009","unstructured":"Goodman, W.A., A.D. Levine, J.V. Massari, H. Sugiyama, T.S. McCormick, and K.D. Cooper. 2009. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. Journal of Immunology 183 (5): 3170\u20133176.","journal-title":"Journal of Immunology"},{"issue":"2","key":"1883_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jdermsci.2015.11.007","volume":"81","author":"L Yang","year":"2016","unstructured":"Yang, L., B. Li, E. Dang, L. Jin, X. Fan, and G. Wang. 2016. Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3. Journal of Dermatological Science 81 (2): 85\u201392.","journal-title":"Journal of Dermatological Science"},{"issue":"7385","key":"1883_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nature10772","volume":"482","author":"SZ Josefowicz","year":"2012","unstructured":"Josefowicz, S.Z., R.E. Niec, H.Y. Kim, P. Treuting, T. Chinen, Y. Zheng, D.T. Umetsu, and A.Y. Rudensky. 2012. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 482 (7385): 395\u2013399.","journal-title":"Nature"},{"key":"1883_CR18","doi-asserted-by":"crossref","unstructured":"Gra\u00dfhoff, H., S. Comd\u00fchr, L.R. Monne, A. M\u00fcller, P. Lamprecht, G. Riemekasten, and J.Y. Humrich. 2021. Low-dose IL-2 therapy in autoimmune and rheumatic diseases. Frontiers in Immunology 12.","DOI":"10.3389\/fimmu.2021.648408"},{"key":"1883_CR19","doi-asserted-by":"crossref","unstructured":"Pol, J.G., P. Caudana, J. Paillet, E. Piaggio, and G. Kroemer. 2020. Effects of interleukin-2 in immunostimulation and immunosuppression. The Journal of Experimental Medicine 217 (1).","DOI":"10.1084\/jem.20191247"},{"issue":"1","key":"1883_CR20","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/s41467-019-08960-1","volume":"10","author":"KH Toomer","year":"2019","unstructured":"Toomer, K.H., J.B. Lui, N.H. Altman, Y. Ban, X. Chen, and T.R. Malek. 2019. Essential and non-overlapping IL-2R\u03b1-dependent processes for thymic development and peripheral homeostasis of regulatory T cells. Nature Communications 10 (1): 1037.","journal-title":"Nature Communications"},{"issue":"7","key":"1883_CR21","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.4049\/jimmunol.2000612","volume":"205","author":"DM Jones","year":"2020","unstructured":"Jones, D.M., K.A. Read, and K.J. Oestreich. 2020. Dynamic roles for IL-2-STAT5 signaling in effector and regulatory CD4+ T cell populations. Journal of Immunology 205 (7): 1721\u20131730.","journal-title":"Journal of Immunology"},{"issue":"7816","key":"1883_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41586-020-2296-7","volume":"583","author":"R Nasrallah","year":"2020","unstructured":"Nasrallah, R., C.J. Imianowski, L. Bossini-Castillo, F.M. Grant, M. Dogan, L. Placek, L. Kozhaya, P. Kuo, F. Sadiyah, S.K. Whiteside, et al. 2020. A distal enhancer at risk locus 11q13.5 promotes suppression of colitis by Treg cells. Nature 583 (7816): 447\u2013452.","journal-title":"Nature"},{"key":"1883_CR23","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.3389\/fimmu.2018.01755","volume":"9","author":"J Luo","year":"2018","unstructured":"Luo, J., B. Ming, C. Zhang, X. Deng, P. Li, Z. Wei, Y. Xia, K. Jiang, H. Ye, W. Ma, Z. Liu, H. Li, X.P. Yang, and L. Dong. 2018. IL-2 inhibition of Th17 generation rather than induction of Treg cells is impaired in primary Sj\u00f6gren\u2019s syndrome patients. Frontiers in Immunology 9: 1755.","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"1883_CR24","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1136\/ard-2022-222501","volume":"81","author":"JY Humrich","year":"2022","unstructured":"Humrich, J.Y., P. Cacoub, M. Rosenzwajg, F. Pitoiset, H.P. Pham, J. Guidoux, D. Leroux, T. Vazquez, G. Riemekasten, J.S. Smolen, et al. 2022. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Annals of the Rheumatic Diseases 81 (12): 1685\u20131694.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"1883_CR25","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/BOR.0000000000000924","volume":"35","author":"R Akbarzadeh","year":"2023","unstructured":"Akbarzadeh, R., G. Riemekasten, and J.Y. Humrich. 2023. Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus. Current Opinion in Rheumatology 35 (2): 98\u2013106.","journal-title":"Current Opinion in Rheumatology"},{"issue":"1","key":"1883_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41392-022-00887-2","volume":"7","author":"X Zhang","year":"2022","unstructured":"Zhang, X., M. Miao, R. Zhang, X. Liu, X. Zhao, M. Shao, T. Liu, Y. Jin, J. Chen, H. Liu, et al. 2022. Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduction and Targeted Therapy 7 (1): 67.","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"8","key":"1883_CR27","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1136\/annrheumdis-2019-216246","volume":"80","author":"SX Zhang","year":"2021","unstructured":"Zhang, S.X., J. Wang, H.H. Sun, J.Q. Zhang, G.Y. Liu, J. Luo, P.F. He, and X.F. Li. 2021. Circulating regulatory T cells were absolutely decreased in dermatomyositis\/polymyositis patients and restored by low-dose IL-2. Annals of the Rheumatic Diseases 80 (8): e130.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"1883_CR28","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","volume":"77","author":"M Miao","year":"2018","unstructured":"Miao, M., Z. Hao, Y. Guo, X. Zhang, S. Zhang, J. Luo, X. Zhao, C. Zhang, X. Liu, X. Wu, et al. 2018. Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome. Annals of the Rheumatic Diseases 77 (12): 1838\u20131840.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"1883_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","volume":"78","author":"M Rosenzwajg","year":"2019","unstructured":"Rosenzwajg, M., R. Lorenzon, P. Cacoub, H.P. Pham, F. Pitoiset, K. El Soufi, C. RIbet, C. Bernard, S. Aractingi, B. Banneville, et al. 2019. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Annals of the Rheumatic Diseases 78 (2): 209\u2013217.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"1883_CR30","doi-asserted-by":"publisher","first-page":"204062232091601","DOI":"10.1177\/2040622320916014","volume":"11","author":"J Wang","year":"2020","unstructured":"Wang, J., S.X. Zhang, Y.F. Hao, M.T. Qiu, J. Luo, Y.Y. Li, C. Gao, and X.F. Li. 2020. The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2. Therapeutic Advances in Chronic Disease 11: 2040622320916014.","journal-title":"Therapeutic Advances in Chronic Disease"},{"issue":"9","key":"1883_CR31","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nm.4148","volume":"22","author":"J He","year":"2016","unstructured":"He, J., X. Zhang, Y. Wei, X. Sun, Y. Chen, J. Deng, Y. Jin, Y. Gan, X. Hu, R. Jia, et al. 2016. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nature Medicine 22 (9): 991\u2013993.","journal-title":"Nature Medicine"},{"issue":"1","key":"1883_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He, J., R. Zhang, M. Shao, X. Zhao, M. Miao, J. Chen, J. Liu, X. Zhang, X. Zhang, Y. Jin, et al. 2020. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases 79 (1): 141\u2013149.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"1883_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.5114\/ada.2020.94838","volume":"37","author":"I An","year":"2020","unstructured":"An, I., D. Ucmak, and M. Ozturk. 2020. The effect of biological agent treatment on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, mean platelet volume, and C-reactive protein in psoriasis patients. Postepy Dermatologii i Alergologii 37 (2): 202\u2013206.","journal-title":"Postepy Dermatologii i Alergologii"},{"issue":"6","key":"1883_CR34","doi-asserted-by":"publisher","first-page":"e14114","DOI":"10.1111\/ijcp.14114","volume":"75","author":"\u0130 An","year":"2021","unstructured":"An, \u0130, M. Aksoy, E. Ayhan, and M. Ozturk. 2021. The effect of secukinumab treatment on inflammatory parameters in patients with psoriasis: a multicentre retrospective study. International Journal of Clinical Practice 75 (6): e14114.","journal-title":"International Journal of Clinical Practice"},{"issue":"3","key":"1883_CR35","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/1346-8138.13061","volume":"43","author":"DS Kim","year":"2016","unstructured":"Kim, D.S., D. Shin, M.S. Lee, H.J. Kim, D.Y. Kim, S.M. Kim, and M.G. Lee. 2016. Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. The Journal of Dermatology 43 (3): 305\u2013310.","journal-title":"The Journal of Dermatology"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-023-01883-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-023-01883-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-023-01883-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T08:17:52Z","timestamp":1700813872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-023-01883-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1883"],"URL":"https:\/\/doi.org\/10.1007\/s10753-023-01883-6","relation":{},"ISSN":["0360-3997","1573-2576"],"issn-type":[{"value":"0360-3997","type":"print"},{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"27 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"DECLARATIONS"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Medical Ethics Committee of the Second Hospital of Shanxi Medical University (2021-YX-010). Written informed consent was obtained from all participates prior to their enrolment in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}